Literature DB >> 12537039

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.

M X Patel1, V Nikolaou, A S David.   

Abstract

BACKGROUND: Maintenance antipsychotic medication is the mainstay of relapse prevention in patients with schizophrenia. Long acting depot antipsychotics were developed to promote treatment adherence and yet their utilization is variable, perhaps due to negative attitudes of both patients and psychiatrists. Recently, a shift away from depots has occurred, in favour of the newer atypical oral antipsychotics.
METHOD: This study investigated the current attitudes and knowledge concerning depots, with a newly designed questionnaire, in a cross-sectional postal survey of qualified psychiatrists working in south-east England.
RESULTS: A substantial minority of psychiatrists believe that depots are old fashioned (40%), stigmatizing (48%) and are associated with more side-effects than typical oral antipsychotics (38%). Many believe that depots are as efficacious as oral medication (91%) but are less acceptable to patients (69%) and relatives (66%). A large majority consider depots enhance patient compliance (81%) and prevent relapse (94%). Psychiatrists would be persuaded to prescribe depots if they were associated with fewer side-effects, in patients where compliance is an issue, and if atypical depot antipsychotics were available, presumably because they would have a lower incidence of side-effects. Additionally, psychiatrists' knowledge about depots was positively associated with attitudes. More favourable patient-centred attitudes were reported by psychiatrists with higher depot use.
CONCLUSION: Practising psychiatrists have several strongly endorsed attitudes towards depot medication that are associated with knowledge and prescribing habits. By updating psychiatrists' knowledge about depots, in turn their attitudes may become more positive and prescribing practices may subsequently change.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12537039     DOI: 10.1017/s0033291702006797

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  28 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  What works in schizophrenia: depot preparations may improve outcomes.

Authors:  Peter M Haddad; Omair Niaz
Journal:  BMJ       Date:  2006-08-12

3.  Use of depot antipsychotic medications for medication nonadherence in schizophrenia.

Authors:  Joyce C West; Steven C Marcus; Joshua Wilk; Lisa M Countis; Darrel A Regier; Mark Olfson
Journal:  Schizophr Bull       Date:  2007-12-18       Impact factor: 9.306

4.  Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.

Authors:  Chen-Chung Liu; Huey-Ling Chiang; Szu-Ying Wu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

6.  Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices.

Authors:  R Christopher Sheldrick; Laurel K Leslie; Angie Mae Rodday; Susan K Parsons; Tully S Saunders; John B Wong
Journal:  J Atten Disord       Date:  2012-11-09       Impact factor: 3.256

7.  Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Alan Jm Brnabic; Richard Newton; Raúl I Escamilla; Liang-Jen Chuo; Malina Simu; Wenyu Ye; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

8.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

9.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

10.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.